10:37 AM EDT, 03/10/2025 (MT Newswires) -- Aurora Spine ( ASAPF ) on Monday said it has completed enrollment in its REFINE study of patients suffering from back pain due to symptomatic degenerative disc disease.

This clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices (Aurora's ZIP Interspinous Fixation System), marking a significant milestone in the advancement of spinal care, the company said.

Data from this pioneering study will be published out to one year, with a subsequent cohort publication extending to two years. The results will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July.

Aurora's shares were last seen down $0.0025, to $0.3225, on the TSX Venture Exchange.